Hydrocortisone, neomycin, phenylephrine, phenylpropanolamine

Listings for this ingredient that could not be applied to this product

• S6: Phenylpropanolamine

  • except products registered in terms of the Act, not intended for export and oral preparations and mixtures where the recommended daily dose for adults does not exceed 100 milligrams and for children 6 to 12 years does not exceed 50 milligrams, when in combination with another pharmacologically active substance and intended for the symptomatic relief of nasal and sinus congestion, subject to a maximum pack size of 300 milligrams for adults and 150 milligrams for children, limited to one pack per customer. (S2)

  Consolidated Schedules 06 July 2026, lines 10387 to 10394

• S4: Hydrocortisone

  • maximum concentration of 1 percent in preparations intended for application to the skin, and
  • in a maximum concentration of 1 percent used in combination with miconazole for topical application in the treatment of athlete’s foot. (S2)

  Consolidated Schedules 06 July 2026, lines 6648 to 6652

• S4: Neomycin

  • except when registered in terms of the provisions of the Fertilizers, Farm Feeds, Agricultural Remedies and Stock Remedies Act, 1947 (Act 36 of 1947).

  Consolidated Schedules 06 July 2026, lines 7224 to 7225

• S4: Phenylephrine

  • when intended for injection
  • except ophthalmic preparations containing 0,2 percent or less. (S0)
  • except for oral dosage forms, nasal dosage forms, or ophthalmic dosage forms containing more than 0,2 percent (S1)

  Consolidated Schedules 06 July 2026, lines 7545 to 7552

• S2: Hydrocortisone

  • maximum concentration of 1 percent in preparations intended for application to the skin, and
  • in a maximum concentration of 1 percent used in combination with miconazole for topical application in the treatment of athlete’s foot. (S4)

  Consolidated Schedules 06 July 2026, lines 2110 to 2114

• S2: Phenylpropanolamine

  • contained in products registered in terms of the Act, and not intended for export, unless listed separately in the Schedules,
  • oral preparations and mixtures where the recommended daily dose for adults does not exceed 100 milligrams and for children 6 to 12 years does not exceed 50 milligrams, when in combination with another pharmacologically active substance and intended for the symptomatic relief of nasal and sinus congestion, subject to a maximum pack size of 300 milligrams for adults and 150 milligrams for children, limited to one pack per customer. (S6)

  Consolidated Schedules 06 July 2026, lines 2516 to 2523

• S1: Phenylephrine

  • when intended for oral dosage forms, nasal dosage forms, or ophthalmic dosage forms containing more than 0,2 percent; (S1)
  • except ophthalmic preparations containing 0,2 percent or less; (S0)
  • except when intended for injection. (S4)

  Consolidated Schedules 06 July 2026, lines 1007 to 1014

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.